Teva Pharmaceutical Industries Ltd (TEVA)
13.96
-0.10
(-0.71%)
USD |
NYSE |
May 07, 16:00
13.96
0.00 (0.00%)
After-Hours: 16:12
Teva Pharmaceutical Industries Enterprise Value: 32.99B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 32.99B |
| May 03, 2024 | 32.90B |
| May 02, 2024 | 33.01B |
| May 01, 2024 | 32.90B |
| April 30, 2024 | 32.98B |
| April 29, 2024 | 33.03B |
| April 26, 2024 | 32.71B |
| April 25, 2024 | 32.08B |
| April 24, 2024 | 31.81B |
| April 23, 2024 | 31.81B |
| April 22, 2024 | 31.67B |
| April 19, 2024 | 31.64B |
| April 18, 2024 | 31.55B |
| April 17, 2024 | 32.00B |
| April 16, 2024 | 31.90B |
| April 15, 2024 | 32.06B |
| April 12, 2024 | 32.14B |
| April 11, 2024 | 32.78B |
| April 10, 2024 | 32.75B |
| April 09, 2024 | 32.89B |
| April 08, 2024 | 33.15B |
| April 05, 2024 | 33.20B |
| April 04, 2024 | 32.84B |
| April 03, 2024 | 33.06B |
| April 02, 2024 | 32.77B |
| Date | Value |
|---|---|
| April 01, 2024 | 32.82B |
| March 28, 2024 | 33.05B |
| March 27, 2024 | 33.40B |
| March 26, 2024 | 33.08B |
| March 25, 2024 | 32.99B |
| March 22, 2024 | 32.80B |
| March 21, 2024 | 32.64B |
| March 20, 2024 | 32.34B |
| March 19, 2024 | 32.19B |
| March 18, 2024 | 32.16B |
| March 15, 2024 | 32.28B |
| March 14, 2024 | 32.36B |
| March 13, 2024 | 32.53B |
| March 12, 2024 | 32.35B |
| March 11, 2024 | 32.19B |
| March 08, 2024 | 32.50B |
| March 07, 2024 | 32.60B |
| March 06, 2024 | 32.40B |
| March 05, 2024 | 32.41B |
| March 04, 2024 | 32.29B |
| March 01, 2024 | 32.36B |
| February 29, 2024 | 31.97B |
| February 28, 2024 | 31.90B |
| February 27, 2024 | 32.14B |
| February 26, 2024 | 32.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
27.05B
Minimum
Jul 03 2023
43.70B
Maximum
May 07 2019
33.29B
Average
33.18B
Median
Jul 16 2021
Enterprise Value Benchmarks
| Viatris Inc | 30.99B |
| Alvotech | 4.969B |
| AstraZeneca PLC | 260.30B |
| Corcept Therapeutics Inc | 2.085B |
| GSK PLC | 105.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 429.00M |
| Revenue (Quarterly) | 4.457B |
| Total Expenses (Quarterly) | 3.17B |
| EPS Diluted (Quarterly) | 0.41 |
| Gross Profit Margin (Quarterly) | 54.18% |
| Profit Margin (Quarterly) | 9.63% |
| Earnings Yield | -3.37% |
| Operating Earnings Yield | 20.37% |
| Normalized Earnings Yield | 11.57 |